New Publication

The proportion of the population taking direct oral anticoagulants (DOACs) is rapidly increasing, and critical clinical situations occur frequently. However, laboratory tests that can rapidly verify clinically relevant drug levels are still not widely implemented. In a comprehensive set of clinical evaluation studies published in the British Journal of Haematology, the study group of Prof. Michael Nagler confirmed that a universal anti-Xa assay accurately estimates rivaroxaban, apixaban, and edoxaban concentrations. Michael Nagler mentioned that “Implementation of the universal assay might simplify laboratory processes, save healthcare costs, and improve care in many patients treated with DOAC”. Read more at: